Nordea Investment Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.68M | Sell |
89,596
-1,115
| -1% | -$71.6K | 0.01% | 549 |
|
|
2026
Q1 | $5.05M | Sell |
90,711
-4,546
| -5% | -$296K | ﹤0.01% | 584 |
|
|
2025
Q4 | $7.62M | Sell |
95,257
-12,570
| -12% | -$845K | 0.01% | 497 |
|
|
2025
Q3 | $5.14M | Buy |
107,827
+4,106
| +4% | +$254K | ﹤0.01% | 582 |
|
|
2025
Q2 | $7.71M | Buy |
103,721
+221
| +0.2% | +$14.6K | 0.01% | 469 |
|
|
2025
Q1 | $6.53M | Sell |
103,500
-675
| -0.6% | -$45.9K | 0.01% | 480 |
|
|
2024
Q4 | $8.15M | Buy |
104,175
+5,385
| +5% | +$433K | 0.01% | 449 |
|
|
2024
Q3 | $7.87M | Sell |
98,790
-5,053
| -5% | -$408K | 0.01% | 450 |
|
|
2024
Q2 | $8.7M | Sell |
103,843
-16,868
| -14% | -$1.48M | 0.01% | 427 |
|
|
2024
Q1 | $10.2M | Sell |
120,711
-2,618
| -2% | -$205K | 0.01% | 420 |
|
|
2023
Q4 | $10.6M | Sell |
123,329
-2,357
| -2% | -$204K | 0.01% | 393 |
|
|
2023
Q3 | $11.6M | Sell |
125,686
-2,192
| -2% | -$196K | 0.02% | 358 |
|
|
2023
Q2 | $10.9M | Buy |
127,878
+6,754
| +6% | +$571K | 0.01% | 385 |
|
|
2023
Q1 | $9.95M | Sell |
121,124
-1,916
| -2% | -$155K | 0.01% | 384 |
|
|
2022
Q4 | $9.64M | Sell |
123,040
-347
| -0.3% | -$27.9K | 0.02% | 381 |
|
|
2022
Q3 | $9.2M | Buy |
123,387
+56,459
| +84% | +$4.05M | 0.01% | 382 |
|
|
2022
Q2 | $4.33M | Buy |
66,928
+7,981
| +14% | +$472K | 0.01% | 566 |
|
|
2022
Q1 | $3.68M | Buy |
58,947
+692
| +1% | +$37.6K | ﹤0.01% | 632 |
|
|
2021
Q4 | $3.15M | Sell |
58,255
-4,953
| -8% | -$302K | ﹤0.01% | 650 |
|
|
2021
Q3 | $4.48M | Buy |
63,208
+577
| +0.9% | +$36.4K | 0.01% | 623 |
|
|
2021
Q2 | $4.17M | Buy |
62,631
+5,623
| +10% | +$398K | 0.01% | 625 |
|
|
2021
Q1 | $6.41M | Buy |
57,008
+1,638
| +3% | +$203K | 0.01% | 509 |
|
|
2020
Q4 | $6.58M | Buy |
55,370
+3,528
| +7% | +$380K | 0.01% | 450 |
|
|
2020
Q3 | $4.46M | Sell |
51,842
-50,862
| -50% | -$4.44M | 0.01% | 513 |
|
|
2020
Q2 | $9M | Buy |
+102,704
| New | +$10.4M | 0.01% | 487 |
|
|
2014
Q3 | – | Sell |
-427,946
| Closed | -$15.1M | – | 843 |
|
|
2014
Q2 | $15.1M | Hold |
427,946
| – | – | 0.06% | 202 |
|
|
2014
Q1 | $13.9M | Sell |
427,946
-24,132
| -5% | -$922K | 0.07% | 195 |
|
|
2013
Q4 | $19M | Buy |
452,078
+25,741
| +6% | +$1.06M | 0.09% | 162 |
|
|
2013
Q3 | $17M | Buy |
426,337
+41,829
| +11% | +$1.75M | 0.09% | 167 |
|
|
2013
Q2 | $15.9M | Buy |
+384,508
| New | +$15.6M | 0.1% | 155 |
|
Other funds holding HAE
AI
Nordea Investment Management's HAE Position: Q2 2026 in Review
Nordea Investment Management reduced its Haemonetics (HAE) stake by 1.2% in Q2 2026, selling an estimated $71.6K and leaving 89,596 shares worth $6.68M. The position accounts for 0.01% of the portfolio, ranked #549.
Nordea Investment Management first reported a position in HAE in Q2 2013 and has held it in 30 quarters since. The position peaked at $19M in Q4 2013. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Nordea Investment Management held 89,596 shares of Haemonetics worth $6.68M as of Q2 2026.
- Nordea Investment Management sold 1,115 Haemonetics shares in Q2 2026, an estimated $71.6K.
- Haemonetics made up 0.01% of Nordea Investment Management's portfolio in Q2 2026, its #549 holding.
- Nordea Investment Management first reported a position in Haemonetics in Q2 2013 and has held it in 30 quarters since.
- Nordea Investment Management's Haemonetics position peaked at $19M in Q4 2013.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.